

The 2023-2028 Outlook for Precision Medicines in China

<https://marketpublishers.com/r/290FAE9B9700EN.html>

Date: August 2022

Pages: 185

Price: US\$ 595.00 (Single User License)

ID: 290FAE9B9700EN

Abstracts

This study covers the latent demand outlook for precision medicines across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as 'regions'). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of 'economic population', as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger than the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this 'economic' definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-?-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for precision medicines. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of precision medicines as including all commonly understood products falling within this broad category, irrespective of product

packaging, formulation, size, or form. Companies participating in this industry include 23andMe, Ab-Biotics Sa, Abbott, Abcodia, ACS Biomarker, Actelion Pharmaceuticals, Advanced Biological Laboratories, Advaxis, Affymetrix, Agendia, Agenus, Alacer Corporation, Alberta Cancer Research Biobank, Alios BioPharma, Inc., Almac, Amgen, Apple, Archimedes, Aspen, Astellas Pharma, AstraZeneca, Astute Medical, Asuragen, AT&T, Athenahealth, Aurora, Auspex Pharmaceuticals, Avon Longitudinal Study of Parents and Children, Bayer, BGI Tech Solutions Company, Ltd., Biocrates Life Sciences, BioFortis, BioGene, Biomerieux, bioMérieux, BioNTech, Bioven International Sdn Bhd, Bode Technology group, Inc., Bristol-Myers Squibb, CareWell Urgent Care, Caris, Celera Diagnostics, Cell & Co Biorepository, Celtics Healthcare, Cepheid, Cetics Healthcare Technologies GmbH, CFR Pharmaceuticals, Ciba-Geigy, Clariant Diagnostic Services, Inc., Cognizant, Cooperative Human Tissue Network, Copan, Covance, Cubist Pharmaceuticals, CureVac, Daiichi Sankyo Company, Dako, Dell, Diabeter, Eagle Genomics, Ltd., Eli Lilly, Estonian Genome Project, F. Hoffmann-La Roche, Ferrer InCode, Ferring Pharmaceuticals, Fisher BioServices, Flakka, Foundation Medicine, GE Healthcare, Genome Medicine, Genomic Health, GenoSpace, Gen-Probe, GlaxoSmithKline, Glooko, Google, Gritstone Oncology, Hologic, Human Tissue Resource Network, HUNT Biobank, IBM, Idera Pharmaceuticals, Illumina, Immatics Biotechnologies, Immuneering Corporation, Immunovative Therapies, Infectio Diagnostic, Inc., Institutional Biobank of Lausanne, Intel, Intomics, Janssen Biotech, Japan Post Group, Johnson & Johnson, Kaiser Permanente, Lab-Ally, Laboratory Corporation of America, LG, Life Technologies, Illumina, Luminex Molecular Diagnostics, Inc., Lutron Electronics, Mayo Clinic, Medpace, Medtronic, Merck, Moderna, Modul-Bio, Molecular Health, Monogram Bioscience, Myriad Genetic Laboratories, Nanosphere, NanoString, NantKwest, Neon Therapeutics, NextWave, Novartis, Omnyx, LLC, OncoMed Pharmaceuticals, Oncotype DX, OneMedNet Corporation, Oracle Healthcare, Panasonic Healthcare, PATH Biobank, Personalis, Pfizer, Philips Healthcare, ProMedDx, Q2 Solutions, Qiagen, Qualcomm, Quest Diagnostics, Randox Laboratories, Reddy Laboratories, Roche, Royal Philips, Samsung, Sandoz, Sanofi Aventis, Siemens Clinical Lab, Signature Diagnostics AG, St. Jude Medical (SJM), Sterand, PLC, Syapse, Sysmex, Takeda Pharmaceutical Company, Tepnel Pharma Services, Teva Pharmaceutical Industries, Therascreen, Thermo Fisher Scientific, Topera, Trofile, U.K. Biobank, UMass Cancer Center Tissue and Tumor Bank, Ventana Medical Systems, Veropharm, Vysis, and Zinfandel Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be

constant in the future at the current level (the average of the year of this publication's release in 2022).

Contents

1 INTRODUCTION

1.1 OVERVIEW

1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?

1.3 THE METHODOLOGY

1.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION

1.3.2 STEP 2. FILTERING AND SMOOTHING

1.3.3 STEP 3. FILLING IN MISSING VALUES

1.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION

1.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION

1.3.6 STEP 6. AGGREGATION AND BENCHMARKING

1.4 FREQUENTLY ASKED QUESTIONS (FAQ)

1.4.1 CATEGORY DEFINITION

1.4.2 UNITS

1.4.3 METHODOLOGY

2 SUMMARY OF FINDINGS

2.1 LATENT DEMAND IN CHINA

2.2 TOP 100 CITIES SORTED BY RANK

2.3 LATENT DEMAND BY YEAR IN CHINA

3 ANHUI

3.1 LATENT DEMAND BY YEAR - ANHUI

3.2 CITIES SORTED BY RANK - ANHUI

3.3 CITIES SORTED ALPHABETICALLY - ANHUI

4 BEIJING

4.1 LATENT DEMAND BY YEAR - BEIJING

4.2 CITIES SORTED BY RANK - BEIJING

4.3 CITIES SORTED ALPHABETICALLY - BEIJING

5 CHONGQING

5.1 LATENT DEMAND BY YEAR - CHONGQING

5.2 CITIES SORTED BY RANK - CHONGQING

5.3 CITIES SORTED ALPHABETICALLY - CHONGQING

6 FUJIAN

6.1 LATENT DEMAND BY YEAR - FUJIAN

6.2 CITIES SORTED BY RANK - FUJIAN

6.3 CITIES SORTED ALPHABETICALLY - FUJIAN

7 GANSU

7.1 LATENT DEMAND BY YEAR - GANSU

7.2 CITIES SORTED BY RANK - GANSU

7.3 CITIES SORTED ALPHABETICALLY - GANSU

8 GUANGDONG

8.1 LATENT DEMAND BY YEAR - GUANGDONG

8.2 CITIES SORTED BY RANK - GUANGDONG

8.3 CITIES SORTED ALPHABETICALLY - GUANGDONG

9 GUANGXI

9.1 LATENT DEMAND BY YEAR - GUANGXI

9.2 CITIES SORTED BY RANK - GUANGXI

9.3 CITIES SORTED ALPHABETICALLY - GUANGXI

10 GUIZHOU

10.1 LATENT DEMAND BY YEAR - GUIZHOU

10.2 CITIES SORTED BY RANK - GUIZHOU

10.3 CITIES SORTED ALPHABETICALLY - GUIZHOU

11 HAINAN

11.1 LATENT DEMAND BY YEAR - HAINAN

11.2 CITIES SORTED BY RANK - HAINAN

11.3 CITIES SORTED ALPHABETICALLY - HAINAN

12 HEBEI

12.1 LATENT DEMAND BY YEAR - HEBEI

12.2 CITIES SORTED BY RANK - HEBEI

12.3 CITIES SORTED ALPHABETICALLY - HEBEI

13 HEILONGJIANG

13.1 LATENT DEMAND BY YEAR - HEILONGJIANG

13.2 CITIES SORTED BY RANK - HEILONGJIANG

13.3 CITIES SORTED ALPHABETICALLY - HEILONGJIANG

14 HENAN

14.1 LATENT DEMAND BY YEAR - HENAN

14.2 CITIES SORTED BY RANK - HENAN

14.3 CITIES SORTED ALPHABETICALLY - HENAN

15 HONG KONG

15.1 LATENT DEMAND BY YEAR - HONG KONG

15.2 CITIES SORTED BY RANK - HONG KONG

15.3 CITIES SORTED ALPHABETICALLY - HONG KONG

16 HUBEI

16.1 LATENT DEMAND BY YEAR - HUBEI

16.2 CITIES SORTED BY RANK - HUBEI

16.3 CITIES SORTED ALPHABETICALLY - HUBEI

17 HUNAN

17.1 LATENT DEMAND BY YEAR - HUNAN

17.2 CITIES SORTED BY RANK - HUNAN

17.3 CITIES SORTED ALPHABETICALLY - HUNAN

18 JIANGSU

18.1 LATENT DEMAND BY YEAR - JIANGSU

18.2 CITIES SORTED BY RANK - JIANGSU

18.3 CITIES SORTED ALPHABETICALLY - JIANGSU

19 JIANGXI

19.1 LATENT DEMAND BY YEAR - JIANGXI

19.2 CITIES SORTED BY RANK - JIANGXI

19.3 CITIES SORTED ALPHABETICALLY - JIANGXI

20 JILIN

20.1 LATENT DEMAND BY YEAR - JILIN

20.2 CITIES SORTED BY RANK - JILIN

20.3 CITIES SORTED ALPHABETICALLY - JILIN

21 LIAONING

21.1 LATENT DEMAND BY YEAR - LIAONING

21.2 CITIES SORTED BY RANK - LIAONING

21.3 CITIES SORTED ALPHABETICALLY - LIAONING

22 MACAU

22.1 LATENT DEMAND BY YEAR - MACAU

22.2 CITIES SORTED BY RANK - MACAU

22.3 CITIES SORTED ALPHABETICALLY - MACAU

23 NEI MONGGOL

23.1 LATENT DEMAND BY YEAR - NEI MONGGOL

23.2 CITIES SORTED BY RANK - NEI MONGGOL

23.3 CITIES SORTED ALPHABETICALLY - NEI MONGGOL

24 NINGXIA

24.1 LATENT DEMAND BY YEAR - NINGXIA

24.2 CITIES SORTED BY RANK - NINGXIA

24.3 CITIES SORTED ALPHABETICALLY - NINGXIA

25 QINGHAI

25.1 LATENT DEMAND BY YEAR - QINGHAI

25.2 CITIES SORTED BY RANK - QINGHAI

25.3 CITIES SORTED ALPHABETICALLY - QINGHAI

26 SHAANXI

26.1 LATENT DEMAND BY YEAR - SHAANXI

26.2 CITIES SORTED BY RANK - SHAANXI

26.3 CITIES SORTED ALPHABETICALLY - SHAANXI

27 SHANDONG

27.1 LATENT DEMAND BY YEAR - SHANDONG

27.2 CITIES SORTED BY RANK - SHANDONG

27.3 CITIES SORTED ALPHABETICALLY - SHANDONG

28 SHANGHAI

28.1 LATENT DEMAND BY YEAR - SHANGHAI

28.2 CITIES SORTED BY RANK - SHANGHAI

28.3 CITIES SORTED ALPHABETICALLY - SHANGHAI

29 SHANXI

29.1 LATENT DEMAND BY YEAR - SHANXI

29.2 CITIES SORTED BY RANK - SHANXI

29.3 CITIES SORTED ALPHABETICALLY - SHANXI

30 SICHUAN

30.1 LATENT DEMAND BY YEAR - SICHUAN

30.2 CITIES SORTED BY RANK - SICHUAN

30.3 CITIES SORTED ALPHABETICALLY - SICHUAN

31 TAIWAN

31.1 LATENT DEMAND BY YEAR - TAIWAN

31.2 CITIES SORTED BY RANK - TAIWAN

31.3 CITIES SORTED ALPHABETICALLY - TAIWAN

32 TIANJIN

32.1 LATENT DEMAND BY YEAR - TIANJIN

32.2 CITIES SORTED BY RANK - TIANJIN

32.3 CITIES SORTED ALPHABETICALLY - TIANJIN

33 XINJIANG UYGUR

33.1 LATENT DEMAND BY YEAR - XINJIANG UYGUR

33.2 CITIES SORTED BY RANK - XINJIANG UYGUR

33.3 CITIES SORTED ALPHABETICALLY - XINJIANG UYGUR

34 XIZANG [TIBET]

34.1 LATENT DEMAND BY YEAR - XIZANG [TIBET]

34.2 CITIES SORTED BY RANK - XIZANG [TIBET]

34.3 CITIES SORTED ALPHABETICALLY - XIZANG [TIBET]

35 YUNNAN

35.1 LATENT DEMAND BY YEAR - YUNNAN

35.2 CITIES SORTED BY RANK - YUNNAN

35.3 CITIES SORTED ALPHABETICALLY - YUNNAN

36 ZHEJIANG

36.1 LATENT DEMAND BY YEAR - ZHEJIANG

36.2 CITIES SORTED BY RANK - ZHEJIANG

36.3 CITIES SORTED ALPHABETICALLY - ZHEJIANG

37 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

37.1 DISCLAIMERS & SAFE HARBOR

37.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS

I would like to order

Product name: The 2023-2028 Outlook for Precision Medicines in China

Product link: <https://marketpublishers.com/r/290FAE9B9700EN.html>

Price: US\$ 595.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/290FAE9B9700EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970